Trial Profile
A clinical trial to measure the cytotoxic activity of lymphocytes increased by dasatinib treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2019
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics
- 04 Feb 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 10 Oct 2011 New trial record